Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALDX NASDAQ:ALT NASDAQ:CSBR NASDAQ:LRMR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$5.56+0.5%$5.19$1.14▼$7.20$333.02M0.8769,846 shs1.06 million shsALTAltimmune$3.78+6.2%$3.91$2.90▼$11.16$333.61M0.182.88 million shs2.65 million shsCSBRChampions Oncology$6.88-28.9%$10.15$3.60▼$11.99$94.23M0.5118,414 shs32,633 shsLRMRLarimar Therapeutics$3.94+1.8%$3.57$1.61▼$9.50$326.15M0.911.33 million shs1.59 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics0.00%-4.79%+7.54%+109.02%-12.03%ALTAltimmune0.00%-1.31%+7.39%-32.74%-41.85%CSBRChampions Oncology0.00%+2.61%+11.78%-0.36%+51.88%LRMRLarimar Therapeutics0.00%+8.84%+7.65%+47.01%-49.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$5.56+0.5%$5.19$1.14▼$7.20$333.02M0.8769,846 shs1.06 million shsALTAltimmune$3.78+6.2%$3.91$2.90▼$11.16$333.61M0.182.88 million shs2.65 million shsCSBRChampions Oncology$6.88-28.9%$10.15$3.60▼$11.99$94.23M0.5118,414 shs32,633 shsLRMRLarimar Therapeutics$3.94+1.8%$3.57$1.61▼$9.50$326.15M0.911.33 million shs1.59 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics0.00%-4.79%+7.54%+109.02%-12.03%ALTAltimmune0.00%-1.31%+7.39%-32.74%-41.85%CSBRChampions Oncology0.00%+2.61%+11.78%-0.36%+51.88%LRMRLarimar Therapeutics0.00%+8.84%+7.65%+47.01%-49.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDXAldeyra Therapeutics 2.67Moderate Buy$9.5070.86% UpsideALTAltimmune 2.57Moderate Buy$17.40360.32% UpsideCSBRChampions Oncology 3.00Buy$12.0074.42% UpsideLRMRLarimar Therapeutics 3.00Buy$18.43367.73% UpsideCurrent Analyst Ratings BreakdownLatest CSBR, ALDX, ALT, and LRMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025LRMRLarimar TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$22.00 ➝ $18.008/13/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.008/13/2025ALTAltimmuneUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$26.00 ➝ $24.008/13/2025ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $18.008/8/2025ALDXAldeyra TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/10/2025ALTAltimmuneThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell7/10/2025ALTAltimmuneJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$25.00 ➝ $15.006/27/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform6/27/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.006/24/2025LRMRLarimar TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/24/2025LRMRLarimar TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$17.00 ➝ $15.00(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDXAldeyra TherapeuticsN/AN/AN/AN/A$1.19 per shareN/AALTAltimmune$20K16,680.57N/AN/A$1.74 per share2.17CSBRChampions Oncology$56.94M1.67$0.46 per share14.91$0.27 per share25.48LRMRLarimar TherapeuticsN/AN/AN/AN/A$2.69 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDXAldeyra Therapeutics-$55.85M-$0.85N/AN/AN/AN/A-73.63%-50.61%11/6/2025 (Estimated)ALTAltimmune-$95.06M-$1.18N/AN/AN/A-438,730.03%-62.63%-55.29%11/11/2025 (Estimated)CSBRChampions Oncology$4.70M-$0.0621.50∞N/A8.26%196.12%16.62%N/ALRMRLarimar Therapeutics-$80.60M-$1.56N/AN/AN/AN/A-62.92%-53.98%10/29/2025 (Estimated)Latest CSBR, ALDX, ALT, and LRMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025LRMRLarimar Therapeutics-$0.47-$0.41+$0.06-$0.41N/AN/A8/12/2025Q2 2025ALTAltimmune-$0.32-$0.27+$0.05-$0.27$0.00 million$0.01 million8/7/2025Q2 2025ALDXAldeyra Therapeutics-$0.21-$0.16+$0.05-$0.16$1.08 millionN/A7/23/2025Q4 2025CSBRChampions OncologyN/A-$0.13N/A-$0.13N/A$12.35 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALDXAldeyra TherapeuticsN/AN/AN/AN/AN/AALTAltimmuneN/AN/AN/AN/AN/ACSBRChampions OncologyN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDXAldeyra TherapeuticsN/A2.862.86ALTAltimmune0.0920.4420.44CSBRChampions OncologyN/A0.940.94LRMRLarimar TherapeuticsN/A5.465.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDXAldeyra Therapeutics59.71%ALTAltimmune78.05%CSBRChampions Oncology41.30%LRMRLarimar Therapeutics91.92%Insider OwnershipCompanyInsider OwnershipALDXAldeyra Therapeutics9.60%ALTAltimmune4.40%CSBRChampions Oncology46.98%LRMRLarimar Therapeutics4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALDXAldeyra Therapeutics1059.90 million54.15 millionOptionableALTAltimmune5088.26 million84.37 millionOptionableCSBRChampions Oncology14313.78 million7.31 millionOptionableLRMRLarimar Therapeutics3082.78 million79.05 millionOptionableCSBR, ALDX, ALT, and LRMR HeadlinesRecent News About These CompaniesDriehaus Capital Management LLC Decreases Stock Holdings in Larimar Therapeutics, Inc. $LRMRSeptember 3, 2025 | marketbeat.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of "Buy" from AnalystsAugust 21, 2025 | marketbeat.comQ4 Earnings Estimate for LRMR Issued By Leerink PartnrsAugust 20, 2025 | marketbeat.comQ3 EPS Forecast for Larimar Therapeutics Lifted by AnalystAugust 19, 2025 | marketbeat.comWilliam Blair Analysts Lift Earnings Estimates for LRMRAugust 19, 2025 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Issues Earnings ResultsAugust 17, 2025 | marketbeat.comResearch Analysts Set Expectations for LRMR FY2028 EarningsAugust 17, 2025 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Price Target Cut to $18.00 by Analysts at JMP SecuritiesAugust 17, 2025 | marketbeat.comLeerink Partners Keeps Their Buy Rating on Larimar Therapeutics (LRMR)August 16, 2025 | theglobeandmail.comLarimar Therapeutics (LRMR) Gets a Buy from Truist FinancialAugust 16, 2025 | theglobeandmail.comLarimar Therapeutics Advances Nomlabofusp Program Toward 2026 FDA FilingAugust 16, 2025 | msn.com3 Best Stocks to Buy Now, 8/15/2025, According to Top AnalystsAugust 15, 2025 | msn.comLarimar Therapeutics Announces $64.4 Million Stock OfferingAugust 15, 2025 | theglobeandmail.comLarimar Therapeutics price target lowered to $18 from $22 at Citizens JMPAugust 15, 2025 | msn.comLarimar Therapeutics Advances Nomlabofusp Program Amid Financial LossesAugust 14, 2025 | tipranks.comLarimar Beats Q2 Loss EstimatesAugust 14, 2025 | aol.comALarimar Therapeutics reports Q2 EPS (41c), consensus (49c)August 14, 2025 | msn.comLarimar Therapeutics Reports Q2 2025 Financial ResultsAugust 14, 2025 | msn.comAltium Capital Management LLC Reduces Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR)August 14, 2025 | marketbeat.comLarimar Therapeutics Reports Second Quarter 2025 Financial ResultsAugust 14, 2025 | globenewswire.comWith 40% stake, Larimar Therapeutics, Inc. (NASDAQ:LRMR) seems to have captured institutional investors' interestAugust 10, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli LillyBy Jordan Chussler | August 9, 2025Medtronic: The Opportunity Gets Healthier for Income InvestorsBy Thomas Hughes | August 19, 2025Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksBy Thomas Hughes | August 19, 2025Palo Alto Networks Uptrend Confirmed! New Highs Set by Year’s EndBy Thomas Hughes | August 19, 2025CSBR, ALDX, ALT, and LRMR Company DescriptionsAldeyra Therapeutics NASDAQ:ALDX$5.56 +0.03 (+0.54%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$5.56 +0.01 (+0.09%) As of 09/5/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Altimmune NASDAQ:ALT$3.78 +0.22 (+6.18%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$3.75 -0.03 (-0.79%) As of 09/5/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Champions Oncology NASDAQ:CSBRChampions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.Larimar Therapeutics NASDAQ:LRMR$3.94 +0.07 (+1.81%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$3.98 +0.04 (+0.91%) As of 09/5/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
